Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Net Income towards Common Stockholders (2020 - 2025)

Ovid Therapeutics' Net Income towards Common Stockholders history spans 6 years, with the latest figure at $9.7 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders rose 204.43% year-over-year to $9.7 million; the TTM value through Dec 2025 reached -$17.4 million, up 34.12%, while the annual FY2025 figure was -$17.4 million, 34.12% up from the prior year.
  • Net Income towards Common Stockholders reached $9.7 million in Q4 2025 per OVID's latest filing, up from -$12.2 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $176.0 million in Q1 2021 to a low of -$26.0 million in Q4 2021.
  • Average Net Income towards Common Stockholders over 5 years is -$1.4 million, with a median of -$11.8 million recorded in 2022.
  • Peak YoY movement for Net Income towards Common Stockholders: surged 978.71% in 2021, then crashed 154.97% in 2025.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$26.0 million in 2021, then surged by 55.75% to -$11.5 million in 2022, then tumbled by 33.18% to -$15.3 million in 2023, then surged by 39.61% to -$9.3 million in 2024, then surged by 204.43% to $9.7 million in 2025.
  • Per Business Quant, the three most recent readings for OVID's Net Income towards Common Stockholders are $9.7 million (Q4 2025), -$12.2 million (Q3 2025), and -$4.7 million (Q2 2025).